Company Filing History:
Years Active: 2004-2006
Title: Innovations of Shengmin Li
Introduction
Shengmin Li is a notable inventor based in Laval, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of peptide ligands for vascular endothelial growth factor receptors. With a total of 3 patents, his work has the potential to impact medical treatments related to angiogenesis.
Latest Patents
One of Shengmin Li's latest patents focuses on a ligand for vascular endothelial growth factor receptor. This invention relates to compositions comprised of a peptide ligand or derivatives that can specifically bind to the high affinity receptor-1 of vascular endothelial growth factor (VEGF) and structurally similar receptors. The invention also provides a peptide ligand or derivatives capable of inhibiting angiogenesis induced by VEGF. Furthermore, it outlines a method for the treatment or diagnosis of diseases associated with angiogenesis in patients, involving the administration of an effective amount of the pharmaceutical composition along with a pharmaceutically acceptable carrier.
Career Highlights
Shengmin Li is currently associated with Supratek Pharma Inc., where he continues to innovate and develop new therapeutic solutions. His expertise in peptide ligands has positioned him as a valuable asset in the biotechnology sector.
Collaborations
Shengmin has collaborated with notable colleagues, including Lioudmila Tchistiakova and Grzegorz Pietrzynski, contributing to a dynamic research environment that fosters innovation.
Conclusion
Shengmin Li's work exemplifies the intersection of innovation and biotechnology, showcasing his commitment to advancing medical science through his patented inventions. His contributions are poised to make a significant impact in the treatment of diseases related to angiogenesis.